



SpePharm appoints Dr. Karl-Gerhard Seifert Chairman of its Supervisory Board

Amsterdam, The Netherlands, 11 December 2007 – SpePharm Holding, B.V., the specialty pharmaceutical company dedicated to the sales and marketing of innovative and specialists' products throughout Europe has appointed, effective December 2007, Dr. Karl-Gerhard Seifert Chairman of its Supervisory Board.

Jean-François Labbé, Chief Executive Officer of SpePharm, commented: "By serving as Chairman of SpePharm Supervisory Board, Karl Seifert is doing the Company a great honour. Karl is internationally recognized and his vast experience in the industry will be invaluable to SpePharm."

SpePharm Supervisory Board consists of four members, all external to the Company:

- Chairman: Dr. Karl-Gerhard Seifert
- Director: Dr. Hubert Birner, Partner, TVM Capital
- Director: James C. Gale, Partner, Signet Healthcare Partners (Sanders Morris Harris Group)
- Director: Bernd Seibel, General Partner, CFO European Operations TVM Capital

About Dr. Karl-Gerhard Seifert

From 1973 to 1997, Dr. Seifert worked for Hoechst AG, a life-sciences company based in Frankfurt, Germany. Dr. Seifert was initially employed as a Plant Manager in both Germany and Brazil, before becoming the Manager and subsequently the Head of the Corporate Staff Department. Dr. Seifert became a member of the Board of Management in 1988, with responsibility for a number of sectors over a nine year period including agriculture, operations in Africa, pharmaceuticals, diagnostics, cosmetics, information and communication and specialty chemicals. In 1997, Dr. Seifert became CEO of Clariant International Limited, a company based in Switzerland dealing in specialty chemicals. In 1999, Dr. Seifert became the Head of Morgan Grenfell Private Equity Ltd. Germany. Since 2001, Dr. Seifert has been the Chairman and CEO of AllessaChemie GmbH. Dr. Seifert is also a member of a number of advisory and supervisory boards. Dr. Seifert holds a degree in Chemistry and a PhD in Physical-Organic Chemistry from the University of Goettingen, and in 1972, pursued a Post-Doctoral Fellowship at IBM, in San Jose, California.

-end-

Media contact:

SpePharm

Jean-François LABBE

Managing Director

Tel: +33 (0) 1 56 60 58 60

jean-francois.labbe@spepharm.com

About SpePharm Holding, B.V.:

SpePharm Holding, B.V. is a Dutch company with its registered office in Amsterdam, and an operational base in Paris, France. SpePharm is an emerging pan-European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines essentially for the hospital and specialty markets. Particularly areas of therapeutic interest are oncology, hematology, critical and supportive care and endocrinology. SpePharm aims to be the preferred partner for pharmaceutical and biotechnology companies, especially those from outside of Europe, seeking to maximize product and commercial opportunities within Europe. SpePharm was founded in September 2006 by Jean-François Labbé together with leading life science investment firms TVM Capital and Signet Healthcare Partners (part of the Sanders Morris Harris Group). Jean-François Labbé is a former top executive at Hoechst Marion Roussel and Parke Davis with over 30 years of experience in international pharmaceutical management. SpePharm, through its founding management team, has a proven track record of

successful development, registration, and/or commercialization of quality therapeutic products in supportive care, oncology and hematology, and orphan diseases. For more information about SpePharm, please visit the web site at www.spepharm.com